Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

BPC-157 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established BPC-157 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. In the interstitial cystitis pilot, the injections were given during a single cystoscopy procedure, with no further treatment reported 10.
  2. The intravenous pilot study administered infusions on two consecutive days (day 1 and day 2), with follow-up blood work and vital signs on day 3 11.
  3. In the knee-pain chart review, follow-up varied because the study was retrospective; most patients had been injected 6 months to 1 year before the telephone survey 9.
  4. The registered rotator cuff study plans injections over 90 days after surgery (NCT07803250); the oral phase 1 record describes a single-dose part and a two-week repeat-dose part (NCT02637284); the completed gummy study ran 8 weeks (NCT07752381) 17,19,20.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • BPC-157 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established BPC-157 cycle length?
No. Human studies administered BPC-157 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of BPC-157?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
BPC-157 dosing reference Full research page

References

  1. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Front Pharmacol. 2021
  2. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Curr Pharm Des. 2018
  3. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth J Orthop Res. 2003
  4. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026 FDA. 2026
  5. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page content current as of 04/22/2026) FDA. 2026
  7. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, questions and briefing documents) FDA Advisory Committee Calendar. 2026
  8. International Standard: Prohibited List 2026 (S0 Non-approved substances; S2 Peptide hormones, growth factors, related substances and mimetics) World Anti-Doping Agency. 2026
  9. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Altern Ther Health Med. 2021
  10. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Altern Ther Health Med. 2024
  11. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Altern Ther Health Med. 2025
  12. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Curr Rev Musculoskelet Med. 2025
  13. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS J. 2025
  14. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation J Mol Med (Berl). 2017
  15. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts Molecules. 2014
  16. FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead (law-firm commentary; secondary source) (summary of FDA advisory committee proceedings) US Food and Drug Administration. 2026
  17. PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284), phase 1, status unknown, no outcome data posted ClinicalTrials.gov. 2015
  18. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety Acta Orthop Belg. 2026
  19. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250), phase 1 registry record, not yet recruiting ClinicalTrials.gov. 2026
  20. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (NCT07752381), completed, no posted results ClinicalTrials.gov. 2025